Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board; Key scientific advisors appointed to support Pionyr's rapidly expanding immuno-oncology therapeutic pipeline

  • Miriam Merad

Press/Media

Period2 May 2022 → 3 May 2022

Media coverage

10

Media coverage